Z

Zenas Biopharma Inc
NASDAQ:ZBIO

Watchlist Manager
Zenas Biopharma Inc
NASDAQ:ZBIO
Watchlist
Price: 9.23 USD -12.59% Market Closed
Market Cap: 385.8m USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+257%
Revenue
Forecast
+147%
Operating Income
Forecast
-12%
Net Income
Forecast
-2%

Wall Street
Price Targets

ZBIO Price Targets Summary
Zenas Biopharma Inc

Wall Street analysts forecast ZBIO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ZBIO is 32.93 USD with a low forecast of 19.19 USD and a high forecast of 47.25 USD.

ZBIO Lowest Forecast
Wall Street Target
19.19 USD
108% Upside
ZBIO Average Forecast
Wall Street Target
32.93 USD
257% Upside
ZBIO Highest Forecast
Wall Street Target
47.25 USD
412% Upside
Lowest
Price Target
19.19 USD
108% Upside
Average
Price Target
32.93 USD
257% Upside
Highest
Price Target
47.25 USD
412% Upside
Zenas Biopharma Inc Competitors:
Price Targets
2256
Abbisko Cayman Ltd
36% Upside
IDYA
IDEAYA Biosciences Inc
169% Upside
BIIB
Biogen Inc
37% Upside
A
397030
AprilBio Co Ltd
117% Upside
2256
Abbisko Cayman Ltd
36% Upside
IDYA
IDEAYA Biosciences Inc
169% Upside
BIIB
Biogen Inc
37% Upside
A
397030
AprilBio Co Ltd
117% Upside
RNA
Avidity Biosciences Inc
121% Upside
6160
Beigene Ltd
6% Upside
PRAX
Praxis Precision Medicines Inc
173% Upside
DTIL
Precision BioSciences Inc
341% Upside

Revenue
Forecast

Revenue Estimate
Zenas Biopharma Inc

For the last 1 year the compound annual growth rate for Zenas Biopharma Inc's revenue is -90%. The projected CAGR for the next 3 years is 147%.

-90%
Past Growth
147%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Zenas Biopharma Inc

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Zenas Biopharma Inc

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

See Also

Summary
ZBIO intrinsic value, competitors valuation, and company profile.
DCF Valuation
ZBIO stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ZBIO stock valuation using valuation multiples.
Wall Street Estimates
ZBIO price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ZBIO stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ZBIO's stock price target?
Price Target
32.93 USD

According to Wall Street analysts, the average 1-year price target for ZBIO is 32.93 USD with a low forecast of 19.19 USD and a high forecast of 47.25 USD.

What is Zenas Biopharma Inc's Revenue forecast?
Projected CAGR
147%

For the last 1 year the compound annual growth rate for Zenas Biopharma Inc's revenue is -90%. The projected CAGR for the next 3 years is 147%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 258,000+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.